Proactive Investors
24 Aug 2026, 09:07 UTC · 2h ago
Oxford Nanopore target price hiked to 196p by Panmure Liberum on strategic pivot
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
24 Aug 2026, 09:07 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Oxford Nanopore Technologies secured a cross-licensing deal with a diagnostics firm providing a $20 million upfront payment and $15 million in committed purchases over two years. — Immediate cash infusion reduces near-term operating losses and provides guaranteed revenue, improving the company's financial stability.
+0.60Iofina PLC expects a 50% increase in crystalline iodine production at its IO#11 plant due to a new brine source. — Significant output expansion typically leads to higher revenue potential and improved margins for a production-based company.
+0.50Panmure Liberum upgraded Oxford Nanopore to a 'buy' rating and raised its target price to 196p from 170p. — Analyst upgrades and target price hikes often serve as positive catalysts for share price appreciation.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Oxford Nanopore's long-term financial goals depend on rapid adoption of its technology by the biopharma sector moving from validation to commercial use. — This identifies a critical strategic risk; failure to convert validation into commercial sales would jeopardize long-term revenue targets.
-0.30Oxford Nanopore reported a narrowed adjusted core loss of £22.1 million for the half-year, beating earnings expectations. — Improving the bottom line and beating estimates indicates better-than-expected operational discipline.
+0.20Which stocks this story touches
Shares jumped over 4% after the company announced a 50% increase in crystalline iodine production at its IO#11 plant.
Received a rating upgrade to 'buy' and a target price hike following a lucrative diagnostics deal and earnings beat.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
4h ago
